PhoreMost applies its proprietary SITESEEKER technology to advance the discovery of novel targets in oncology and Targeted Protein Degradation.

PhoreMost

PhoreMost Ltd | 5,276 followers on LinkedIn. Drugging the Undruggable® | PhoreMost is a new-model drug discovery company based in Cambridge, UK. We are dedicated to ‘Drugging the Undruggable®’ disease targets using our next-generation technology, SITESEEKER®. Using PROTEINi® libraries, this unique drug target identification platform can discern the best new targets for future therapy and crucially, how to drug them, which has the potential to significantly increase the diversity and affordability of novel therapeutics for cancer and other unmet diseases.

Investor at BGF

Tim Rea

Partner @ Amadeus Capital

Pierre Socha

Associate Director of Drug Discovery at PhoreMost Ltd

Miguel Coelho

CEO at PhoreMost Ltd

Neil Torbett

PhoreMost Ltd

📢 A rational approach to molecular glue discovery: GlueSEEKER™ Molecular glues are an emerging class of innovative drug that exploit the cell’s proteostasis mechanisms by inducing close proximity between a target protein and an effector protein (like an E3 ligase). This effectively glues them together. These small molecule drugs have so far only been discovered by serendipity. To address this challenge, we have developed GlueSEEKER. Expanding on our SITESEEKER platform, GlueSEEKER integrates computational approaches with molecular biology to systematically identify new molecular glue targets, expanding the scope for this important modality and helping us to bring new precision medicines to fruition faster. Learn more on our website: https://rb.gy/o2vyjf

We had a great time at the TPD and Induced Proximity Summit, hearing about the latest advances in molecular glues, degrader therapeutics, and novel protein degradation mechanisms, as well as sharing updates on our internal pipelines. Didn’t manage to catch our presentations? Contact us to learn more about our innovative approaches to drug discovery: 📩 info@phoremost.com 💻 www.phoremost.com #TPD #MolecularGlues #DegraderTherapeutics

This week, Dr Neil Torbett and Dr Ian Hutchison are in Stockholm for #BIOEurope Autumn, meeting with leaders from across the life science industry to discuss the latest opportunities for collaborative innovation. Interested in learning more about how we are enabling the discovery of novel degrader therapeutics? Get in touch to schedule a meeting: info@phoremost.com #TPD #DrugDiscovery #LifeScience

“The next decade promises further innovation, particularly with the rational design of molecular glues” Dr Benedict CS Cross , CTO, spoke with The Medicine Maker and provided insight exploring innovations in molecular glues and how they will improve therapeutic outcomes by overcoming pharmacokinetic limitations of bivalent degraders and expanding the druggable space. 📰 Read the full article: https://lnkd.in/ecQSjFuE #MolecularGlues #DrugDiscovery #Innovation

Our team has arrived in Boston for the TPD and Induced Proximity Summit! Be sure to catch our presentations: Neil Torbett , CEO 🎤 Visions for the future of TPD and Beyond: the CEO perspective 🎤 CEO Think Tank: a strategic look at TPD and induced proximity field Christian Dillon , CSO 📆 30th Oct, 11:30am EDT 🎤 Discovery of Bifunctional Degraders Operating Through the CUL1/SKP1 SCF Complex Benedict CS Cross , CTO 📆 31st Oct, 1:30pm EDT 🎤 A Systematic Protein Editing Platform to Unlock Molecular Glue Discovery #TPD #MolecularGlues #DegraderTherapeutics

💡 A brilliant idea for helping cancer patients is just that – an idea – until it is put into practice. This latest article from University of Cambridge explores 10 of its spinouts changing the story of cancer, including PhoreMost. Being based in Cambridge allows us to be supported by the University’s innovation arm, Cambridge Enterprise , which is engaging with academics, entrepreneurs, and venture funds to drive the development of more effective and targeted oncology therapeutics. Read more: https://lnkd.in/eFsBQGcf #Oncology #DrugDevelopment #ChangingTheStoryOfCancer

📢 Join our team! Are you an innovative Computational Chemist looking for an exciting new opportunity in small molecule drug discovery? We’re recruiting for a Senior/Principal Computational Chemist to join our Drug Discovery team, based in our labs at Unity Campus Cambridge. Responsibilities include: 🧪 Onboarding new methodologies to be integrated into our platform 🧪 Providing computational chemistry support for the design of high-quality molecular glue and PROTAC molecules 🧪 Supporting the Target Discovery team with protein modelling Find out more and apply: https://lnkd.in/gt8gd9-i #CambridgeJobs #DrugDiscovery #ComputationalChemistry

Introducing 10 Cambridge spinouts changing the story of cancer. 🌟 A brilliant idea for helping cancer patients is just that - an idea - until it is put into practice. Turning research into something that can improve patient outcomes and benefit healthcare systems around the world is not easy. At Cambridge Enterprise, we support spinouts from the University of Cambridge through their commercialisation journey. Being part of the UK’s leading life sciences cluster provides plenty of inspiration, access to investors and talent, and the guidance of others who have gone before. Meet 10 of our spinouts, all committed to making a real difference: • T-Therapeutics Ltd • Concr • 52North - creators of Neutrocheck® • PhoreMost Ltd • STORM Therapeutics Limited • Verinnogen • Spirea • biomodal • PharmEnable Therapeutics • Astex Pharmaceuticals 👉🏼 Read more about how they are are driving the future of cancer treatment: https://vist.ly/3mj67du #CancerResearch #Healthcare #LifeSciences #UniversityOfCambridge #Innovation

Cambridge Enterprise

Not long to go until the TPD and Induced Proximity Summit! Our team has a busy schedule of presentations and panel discussions planned, including: Neil Torbett , CEO 📆 29th Oct, 8:15am EDT 🎤 Visions for the future of TPD and Beyond: the CEO perspective 📆 29th Oct, 9:30am EDT 🎤 CEO Think Tank: a strategic look at TPD and induced proximity field Christian Dillon , CSO 📆 30th Oct, 11:30am EDT 🎤 Discovery of Bifunctional Degraders Operating Through the CUL1/SKP1 SCF Complex Benedict CS Cross , CTO 📆 31st Oct, 1:30pm EDT 🎤 A Systematic Protein Editing Platform to Unlock Molecular Glue Discovery Find out more here: https://lnkd.in/ezfvZeeF #TPD #MolecularGlues #DrugDiscovery

Thank you Business Weekly newspaper for including us in the latest Life Science Killer50 list! The list celebrates Cambridge’s most innovative life science companies, reflecting the exciting potential of our SITESEEKER and GlueSEEKER platforms to develop the next generation of degrader therapeutics. Find out more on our website: www.phoremost.com #DrugDiscovery #TPD #MolecularGlues

news impact assignment basic	general
public peers	general	Nov 8, 2024 4:33 PM	425a1f82
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 8, 2024 4:33 PM	e9393ae7
crunchbase trigger	general	Nov 25, 2024 9:09 AM	6680b5b6
crunchbase profile	general	Nov 25, 2024 10:11 AM	e03ee700
li profile	general	Nov 8, 2024 4:33 PM	e7174851
translate crunchbase fundingrounds	general
peers	general	Nov 8, 2024 4:33 PM	b105ddfd
news basic	general	Nov 8, 2024 4:33 PM	ee55e215
bundesanzeiger	filings
financials download nd	financials
private financials	financials

PHOR

COM:PHOREMOST

PhoreMost